



THE UNITED STATES PATENT AND TRADEMARK OFFICE

1644
RECEIVED

In the Application of:

Kenneth A. Brasel, Stewart D. Lyman,
Eugene Maraskovsky, Hilary J. McKenna,
David H. Lynch and Charles R.
Maliszewski

Docket No.: 2836-D

JAN 09 2002

Group Art Unit: 1644

TECH CENTER 1600/290X

Examiner: Phillip Gambel

#21/F
gnd
8/16/02

Serial No: 09/448,378

Filed: November 23, 1999

CPA Filed: June 28, 2001

For: DENDRITIC CELL STIMULATORY FACTOR

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the Office Action, having a mailing date of October 9, 2001, Applicants respectfully submit the following within the one-month period for reply ending November 9, 2001. Applicants elect Group I (claims 6, 7, 20 and 22-53) for examination and withdraw claims 54-56 without prejudice. Applicants reserve the right to pursue claims 54-56 in future applications. Applicants respectfully request reconsideration and allowance of the pending claims.

Kindly amend the application as follows:

In the Specification:

Please replace the title of the invention at page 1, with the following:

-- Methods of Using Flt3-Ligand for Augmenting an Immune Response for the Treatment of Cancer --

Kindly amend the cross-reference to related applications at page 1 as follows:

-- This is a divisional application of U.S. S/N 08/725,540 filed February 22, 1999, now abandoned, which is a continuation-in-part of U.S. S/N 08/539,142 filed October 4, 1995, now abandoned. --

changed
up
Palm